Absci Corporation Common Stock (ABSI) — Analysis Summary
Absci Corporation Common Stock (ABSI) has a market cap of $1.73B with year-over-year revenue growth of -38.2%. Net margin stands at -4113.7%. The stock trades at a P/E ratio of -14.6.
Key Takeaways
- Revenue changed -38.2% year-over-year
- Net margin of -4113.7%
- P/E ratio of -14.6
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, ABSI posted revenue growth of -38.2% and trades at a P/E of -14.6.
Absci Corporation Common Stock (ABSI)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -834.0x — earnings do not cover interest payments
Operating margin at -6723.0% — severe operating losses
Net margin at -6450.8% — losses exceed revenue (possible one-time charges)
Revenue fell 34.4% vs the prior period.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
140
Headquarters
VANCOUVER, WA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.